<DOC>
	<DOC>NCT00605644</DOC>
	<brief_summary>The primary purpose of this study is to evaluate the safety and dose-response relationship of N-methylnaltrexone bromide (MOA-728) by observing spontaneous bowel movements in subjects administered MOA-728 who have chronic pain that is not due to cancer, and who have opioid-induced bowel dysfunction (OIBD).</brief_summary>
	<brief_title>Study Evaluating MOA-728 Oral for the Treatment of OIBD in Subjects With Chronic Non-Malignant Pain</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>Adult Outpatients with opioidinduced bowel dysfunction and chronic pain, which is not due to malignant cancer. Taking oral, transdermal, intravenous, or subcutaneous opioids. Willingness to discontinue all prestudy laxative therapy and use only study permitted rescue laxatives. History of chronic constipation before the initiation of opioid therapy. Other GI disorders known to affect bowel transit. Women who are pregnant, breast feeding, or plan to become pregnant.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>